Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This is a phase II, single arm, open-label, multicenter study to evaluate the efficacy and
safety of Sintilimab combined with IBI310 and Surufatinib for the treatment of high-grade
advanced-neuroendocrine neoplasm